Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic

Johnson, A.P.

Current Opinion in Investigational Drugs 8(2): 168-173

2007


ISSN/ISBN: 1472-4472
PMID: 17328233
Document Number: 610710
Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum macrocyclic antibiotic secreted by the actinomycete Dactylosporangium aurantiacum, for the potential treatment of Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus infection. A phase IIb/III clinical trial of OPT-80 in patients with CDAD is underway.

Document emailed within 1 workday
Secure & encrypted payments